Reading the retatrutide phase 2 data properly rather than the headline, and the 24% figure is doing a lot of work that the confidence interval does not support as firmly as people think.
The bit I cannot resolve on my own is what the phase 2 dropout pattern implies about how the phase 3 tolerability will read.
I would rather have one careful answer than five confident ones.
Answering the narrow version, because the broad one does not have a single answer. Order of operations matters more than any single choice here: establish a baseline, change one thing, wait long enough for it to express itself, then measure again under the same conditions.
If somebody has the primary source to hand I would rather cite it than paraphrase it.
LipidDoc_ATL said:Order of operations matters more than any single choice here: establish a baseline, change one thing, wait long enough for it to express itself, then…
LipidDoc_ATL has the substance of this right. The condition it depends on is worth stating. The phase 2 numbers were about 24% mean weight loss at 48 weeks on the top dose, with the curve still descending at the end of the study. A curve that has not flattened is a real finding, but it also means the true plateau is unknown, and phase 2 populations are small and selected.
Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.
Verify Your PeptidesEst. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.
Browse GL Biochemnick_newbie said:Reading the retatrutide phase 2 data properly rather than the headline, and the 24% figure is doing a lot of work that the confidence interval does…
Same experience, arrived at from the opposite direction.
Adding the clinical framing, because it changes how the question reads. The mechanism and the magnitude are separate questions. Agreeing that something happens says nothing about whether it happens enough to act on.